Clinical Trial: Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer

U.S., Sept. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07170982) titled 'Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer' on Sept. 05.

Brief Summary: This is a randomized, controlled, multicenter clinical study designed to explore the safety and efficacy of fruquintinib combined with standard chemotherapy versus standard chemotherapy as first-line treatment for advanced mismatch repair-intact (pMMR) endometrial cancer. The standard chemotherapy regimen is TC (paclitaxel + carboplatin);

Safety introduction period (N=12):

Dose expansion phase (N=116): Subjects who met the inclusion criteria were randomly assigned ...